An item in the ASH Roundup in BioWorld Today, Dec. 8, 2009, should have stated that Ambit Biosciences Corp.'s FMS-like tyrosine kinase-3 inhibitor is in development for acute myeloid leukemia.

Editor's note: The correction has been made in BioWorld Online.